




































3.   INNOVATE 








\*                         




- 1.   1304 
- 2.   1307 
- 3.   INNOVATE 

### 3. INNOVATE <sup>1</sup>


























INNOVATE INvestigation of Omalizumab in seVere Asthma TrEatment

1 **Humbert, M. et al.: Allergy 60** 3, 309, 2005 **XOLM00426**       

1 



   $\beta$ 2                       





 28               




4. 増悪頻度の比較  
 5. 増悪頻度の比較  
 <増悪頻度>  
 5.1 増悪頻度の比較  
 増悪頻度  
 • 増悪頻度の比較  
 • 増悪頻度の比較  
 • 増悪頻度の比較  
 6. 増悪頻度の比較  
 <増悪頻度>  
 増悪頻度の比較  
 増悪頻度の比較  
 増悪頻度の比較  
 増悪頻度の比較  
 増悪頻度の比較  
 増悪頻度の比較  
 7. 増悪頻度の比較  
 <増悪頻度>  
 7.5 増悪頻度の比較

2. 増悪頻度の比較

PITT 増悪頻度の比較 28 増悪頻度の比較  $p=0.042$  増悪頻度の比較

Image



増悪頻度の比較

2. INNOVATE 増悪頻度の比較  
 28 増悪頻度の比較

3. 増悪頻度の比較

増悪頻度の比較 72.2% 177/245 増悪頻度の比較 75.5% 179/237 増悪頻度の比較  
 増悪頻度の比較 27 11.0% 増悪頻度の比較 24 10.1% 増悪頻度の比較 24 9.8% 増悪頻度の比較 22 9.3% 増悪頻度の比較  
 増悪頻度の比較 3 1.3% 増悪頻度の比較 13 5.3% 増悪頻度の比較 1 0.4% 増悪頻度の比較  
 増悪頻度の比較 11 4.5% 増悪頻度の比較 / 増悪頻度の比較 / 増悪頻度の比較 / 増悪頻度の比較  
 増悪頻度の比較 / 増悪頻度の比較 / 増悪頻度の比較 C 増悪頻度の比較 1 0.4% 増悪頻度の比較 4  
 1.7% 増悪頻度の比較 / 増悪頻度の比較 1 0.4% 増悪頻度の比較

1. 増悪頻度の比較 1304
2. 増悪頻度の比較 1307
3. 増悪頻度の比較 INNOVATE 増悪頻度の比較

□□□□□

□□□□□

□□□□

□□□□□□□□□□

□□□□□□□□□□

PFS□□□□

□□□□□□□□

□□□□□□□□□□

IC□□□□□□□□□□□□

IC□□□□□□□□□□□□

□□□□□□

□□□□□□□□□□□□□□□□□□□□□□

□□□□□□□□□□□□□□□□□□□□□□

□□□□□□□□

IgE□□□□□□

Image

患者向けサイト >  
気管支喘息



---

**Source URL:** [https://www.pro.novartis.com/jp-ja/products/xolair/asthma/clinical\\_03](https://www.pro.novartis.com/jp-ja/products/xolair/asthma/clinical_03)